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DECODING THE SYMPATHETIC NERVOUS SYSTEM’S REGULATION OF WHITE
ADIPOSE TISSUE HYPERPLASIA

by

MARY K. SCHNEIDER

Under the Direction of Hang Shi, Ph.D.

ABSTRACT
Adipose tissue (AT) expands via both hypertrophy and hyperplasia during the
development of obesity. While AT hypertrophy involves the increase in size of existing
adipocytes, hyperplasia is the process of creating new adipocytes from the pool of adipocyte
precursor cells (APCs) which includes adipocyte progenitor cells and preadipocytes. Prior
studies have implicated a role of the sympathetic nervous system (SNS) in regulation of
hyperplasia in white adipose tissue (WAT). These studies were not specific to APCs, however,
and lacked characterization of the signaling intermediaries. Here we aimed to determine the
mechanisms underlying SNS regulation of APC proliferation in WAT. Using flow cytometry
with antibodies against various cell surface markers, along with an intracellular marker of

proliferation (Ki67), we quantitated the percentages and proliferative status of adipocyte
progenitor cells and preadipocytes in the stromal vascular fraction (SVF) of WAT. In vivo SNS
activation through cold exposure, as well as in vitro adrenergic stimulation via exposure to the
canonical SNS neurotransmitter norepinephrine (NE), inhibited preadipocyte proliferation.
Pretreatment with propranolol, a β1- and β2-adrenergic receptor (AR) antagonist, rescued the
inhibitory effects of NE in primary cell culture. The selective β1-AR agonist dobutamine
diminished preadipocyte proliferation both in vivo and in vitro, whereas the selective β2-AR
agonist, salbutamol, promoted proliferation in vitro, suggesting that the β1-AR may mediate the
inhibitory effect of NE on preadipocyte proliferation. We further explored the downstream
signaling by pretreating cultured SVF cells with an adenosine monophosphate-activated protein
kinase (AMPK) blocker, Compound C (CC). CC prevented the inhibitory effect of dobutamine
on preadipocyte proliferation as compared with relative controls. Taken together, we conclude
that SNS activation suppresses WAT preadipocyte proliferation via the β1-AR and that
downstream signaling may include AMPK activation.

INDEX WORDS: Proliferation, Adipocyte progenitors, Preadipocytes, Adrenergic receptor,
Norepinephrine, Flow cytometry
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1
1.1

INTRODUCTION

Obesity
Obesity is increasingly prevalent and is associated with severe health complications.

Among the comorbidities of obesity are cardiovascular disease, diabetes, and cancer, which
account for three of the four most deadly noncommunicable diseases today (Pi-Sunyer 1999,
Nishida, Ko et al. 2010). The prevalence of obesity has risen dramatically in the United States in
the past several decades, with the present incidence of obesity in adults hovering between 3540%, according to analyses of data from the National Health and Nutrition Examination Survey
(Flegal, Kruszon-Moran et al. 2016). In American women, the incidence of obesity showed a
linear upward trend from 2005-2014. American adolescents were diagnosed with obesity at a
steadily increasing rate from 1988-2014 (Ogden, Carroll et al. 2016). As countries across the
world become more urbanized, global obesity rates have also climbed to an alarming level. It has
now been determined to be the fifth-leading cause of death worldwide (Ng, Fleming et al. 2014).
Obesity is a serious economic burden as well. Medical costs due to obesity and its complications
currently account for more than one-fifth of total healthcare expenses in the U.S. (Cawley and
Meyerhoefer 2012).
Defined as having a Body Mass Index (BMI) of greater than 30 kg/m2, obesity develops
in response to a prolonged state of energy imbalance as a result of excess caloric intake over
energy expenditure (Tataranni and Ravussin 1997, Jensen, Ryan et al. 2014). The body’s most
efficient storage depot for the additional, unneeded calories is white adipose tissue (WAT) and
research has shown that decreasing WAT mass specifically can greatly reduce, if not negate, the
harmful effects of obesity (Adams, Gress et al. 2007, Rider, Francis et al. 2009). WAT mass
reduction is ideally accomplished through the adoption of a well-balanced, low-calorie diet in
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combination with increased activity levels. A significant proportion of individuals find this
strategy very difficult to maintain, however. In many cases the obese patient with severe
comorbidities is prescribed medication that can hinder weight loss efforts. For example, those
with Type 2 Diabetes are often in need of insulin therapy, which promotes weight gain and
further compounds the problem (Apovian, Aronne et al. 2015). Given the challenges and variable
outcomes associated with the current recommended approaches such as restrictive diet and
pharmacotherapy, and the urgent need to reverse the trajectory of the obesity epidemic, research
is warranted to define alternative means by which WAT mass can be effectively decreased. To
uncover additional approaches to WAT mass reduction, we must improve upon our
understanding of WAT biology.
1.2

White adipose tissue
Once thought to be mostly inert, adipose tissue (AT) is now known to be quite dynamic

(Fliers, Kreier et al. 2003). WAT bears the burden of obesity, as one of its major functions is the
storage of excess energy in the form of triglycerides (TGs). Adipocytes are the mature AT cells
that actively take up fatty acids, esterify them to a glycerol backbone to form TGs, and sequester
the TGs in vacuoles known as lipid droplets (LDs). When energy substrates are needed by other
tissues in the body, WAT releases non-esterified fatty acids (NEFAs) through the breakdown of
TGs in a process known as lipolysis (Ahmadian, Wang et al. 2010). WAT is also considered to
be the largest endocrine organ of the body in that it produces and disseminates proteins and
hormones known as adipokines (Bloor and Symonds 2014). Appetite-regulating adipokines, such
as leptin and adiponectin, have substantial influence over body weight maintenance and are often
dysregulated in obesity (Friedman 2016, Lopes, Correa-Giannella et al. 2016, Knebel, Goeddeke
et al. 2017).
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The cellular makeup of WAT varies beyond the adipocyte. The constitution of WAT can
be defined by two fractions: the adipose fraction, where mature adipocytes are found, and the
stromal vascular fraction (SVF), where a plethora of additional cell types are located (Church,
Berry et al. 2014). While adipocytes consume the majority of the physical space in WAT, they
are far outnumbered by the cells contained within the SVF (Eto, Suga et al. 2009). Cell types in
the SVF include, but are not limited to, adipose-derived stem cells (ADSCs), fibroblasts,
hematopoietic cells, endothelial cells, macrophages, lymphocytes, neural cells and epithelial
cells, serving various mechanistic and supportive functions for the tissue (Hausman, DiGirolamo
et al. 2001, Smith, Fairbridge et al. 2015). The resident stem cell population, ADSCs, are
multipotent and have the capacity to develop along an osteogenic, myogenic or adipogenic
lineage. When ADSCs commit to the adipocyte lineage, they first mature into adipocyte
progenitors. Adipocyte progenitors can then further differentiate into preadipocytes, the
immediate precursor to the adipocyte. Adipocyte progenitors and preadipocytes are collectively
referred to as adipocyte precursor cells (APCs) (Berry and Rodeheffer 2013). In the final step of
differentiation, preadipocytes mature into adipocytes, at which point it is believed they are no
longer able to divide and multiply (Spalding, Arner et al. 2008, Algire, Medrikova et al. 2013).
1.3

WAT expansion
Enlargement of WAT depots can be accomplished in either or both of two ways. The first

means of growth is by increasing the size of existing adipocytes and the second is by increasing
the number of cells. These processes are known as “hypertrophy” and “hyperplasia,”
respectively. AT expansion by hypertrophy can accommodate the need for additional TG storage
through the expansion of LDs, yielding adipocytes with larger diameters. The extent to which an
adipocyte can stretch its plasma membrane for growing LDs has physical limitations, however
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(Leonhardt, Hanefeld et al. 1972). Hyperplastic AT growth, also known as adipogenesis, occurs
when APCs undergo mitosis, proliferation and differentiation to increase the quantity of fat cells.
Hyperplasia offers WAT the opportunity to extend its capacity to even greater lengths than
hypertrophy alone (Faust, Johnson et al. 1978). As the imbalance between energy consumed over
energy expended persists, more storage space is needed and APCs can be mobilized to
differentiate into mature adipocytes for this purpose. Although the processes of differentiation
into mature adipocytes and hypertrophy have been studied extensively, the mechanisms driving
APC proliferation are much less well understood. A potentially powerful therapeutic approach to
combating the increase in WAT mass is understanding the regulation of WAT hyperplasia.
1.4

Neural regulation of WAT expansion
WAT is directly innervated by sympathetic nerves arising from the sympathetic ganglion

chain as evidenced early in studies of morphological patterns and more recently by neuronal tract
tracing (Ballard, Malmfors et al. 1974, Youngstrom and Bartness 1995). The sympathetic
nervous system (SNS) releases norepinephrine (NE) from its axon terminals into WAT, where it
binds to adrenergic receptors (ARs) expressed on the plasma membranes of cells residing in
WAT, including APCs. In addition to the well-defined role that the SNS plays in stimulating
lipolysis after binding to adipocyte ARs, previous research has implicated the SNS in limiting
WAT growth. Through its neurotransmitter NE, the SNS likely inhibits WAT preadipocyte
proliferation (Jones, Ramsay et al. 1992, Cousin, Casteilla et al. 1993, Foster and Bartness 2006).
An in vitro study using primary cell culture of rat inguinal WAT (IWAT) found that NE
exposure significantly decreased preadipocyte proliferation. In this study, knowing that brown
adipocyte proliferation is regulated by β-adrenergic agonists, Jones et al., questioned whether or
not a similar relation between β-ARs and proliferation exists in WAT (Geloen, Collet et al. 1988,
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Jones, Ramsay et al. 1992). Primary cultures of rat preadipocytes were treated with or without
NE. After two days, NE inhibited proliferation when compared to controls. NE is known to
activate both α- and β-ARs. To parse out the receptor subtype through which NE exerts its antiadipogenic effects, cells were pretreated with the β1- and β2-AR antagonist propranolol just prior
to incubation with NE. Pretreatment with propranolol rescued the inhibitory effect of NE,
implicating the β1- or β2-AR as the receptor that NE binds in order to inhibit preadipocyte
proliferation. Furthermore, pretreatment with phenoxybenzamine, a non-specific α-AR
antagonist, followed by NE exposure, did not reverse NE’s inhibitory effect. The experiments
performed by Jones et al., implicate either the β1 or β2-AR as the receptor subtype through which
NE exerts its effects.
From the opposite perspective, it has been demonstrated that a lack of SNS innervation to
WAT increases preadipocyte proliferation. Unilateral surgical denervation of the retroperitoneal
fat pad in rats was performed, while innervation to the contralateral retroperitoneal fat pad was
left intact and used as a within-subject control (Cousin, Casteilla et al. 1993). The researchers
found that cell number increased in the denervated fat pad in comparison to the innervated fat
pad. They isolated cells from each fat pad and probed for mRNA expression of the human α2
chain of type VI collagen (A2COL6) gene. The A2COL6 gene has been shown to be upregulated
in preadipocytes (Ibrahimi, Bertrand et al. 1993). Quantification of A2COL6 expression revealed
that the denervated fat pads had significantly enhanced levels of this gene, implying that the
increase in cell number was due at least in part to an increase in preadipocyte proliferation.
In our lab, this work was taken a step further. In Siberian hamsters, unilateral SNS
innervation to IWAT was either surgically or chemically ablated, while the contralateral IWAT
pad was subjected to the same surgical manipulation but the nerves supplying it remained
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untouched (Foster and Bartness 2006). This effectively negated the supply of NE to the
denervated IWAT pad. The thymidine analog 5-bromo-2’-deoxyuridine (BrdU) was injected
subcutaneously. BrdU is incorporated into the DNA of newly replicated cells and was
immunohistochemically identified in order to quantify proliferative effects on IWAT in this
study. To confirm that BrdU-labeled cells were of adipose origin, the adipocyte membranespecific protein marker AD3 was also labeled, and those cells that were positively labeled for
both BrdU and AD3 were deemed preadipocytes that had undergone proliferation and
differentiation. Challenges were encountered in the identification of dual-labeled cells, possibly
due to extensive denaturing of proteins that occurred as a result of the heat-induced cell
membrane permeabilization protocol that was used to access DNA prior to AD3 staining.
Regardless, in comparison to control innervated fat pads, the denervated fat pads exhibited an
~300% increase in fat cell number. This was attributed to the absence of sympathetic nerves
interacting with the IWAT pad and the subsequent lack of NE available to inhibit hyperplasia.
The approaches utilized in these previous studies for the detection of preadipocytes have
some limitations, such as issues in resolving antibody labeling and macrophage infiltration, which
render it necessary to conduct additional testing (Tchoukalova, Fitch et al. 2012, Berry, Jeffery et
al. 2014). The mechanism underlying SNS inhibition of preadipocyte proliferation also has yet to
be defined.
1.5

Hypotheses
We hypothesize that the SNS regulates WAT APC populations and proliferation through

either or both the β1- and β2-adrenergic receptors. We further hypothesize that adenosine
monophosphate-activated protein kinase (AMPK) is an intracellular effector involved in
mediating the effects of the SNS. To test our hypotheses, we developed the following specific
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aims.
1.6

Specific Aims
We examined the impact of SNS activation on WAT hyperplasia in vivo with cold

exposure studies and AR-agonist injections. We assessed the ability of NE, as well as selective
β1- and β2-AR-ligands and antagonists, to alter APC proliferation in primary cell culture. We
also utilized pharmacological activators and blockers to test intracellular signaling molecules,
including AMPK, which have been implicated in cell cycle regulation and could be mediating
the inhibitory effect of the SNS on adipogenesis.
To address technical issues that we and others had with the methodologies of prior
studies, we adopted multicolor flow cytometry for analyses of effects on APCs. Flow cytometry
is a more sensitive approach that can quantitatively distinguish between adipocyte progenitors
and preadipocytes in the pool of APCs using specific antibodies against their cell surface
markers (Berry, Jeffery et al. 2014, Church, Berry et al. 2014). We expanded upon this
specificity with intracellular staining of the protein Ki67, a marker for cell proliferation
(Scholzen and Gerdes 2000, Hui, Gu et al. 2015, Fukano, Okamatsu-Ogura et al. 2016). This
methodology allows us to ascertain distinct impacts on the proliferative status of adipocyte
progenitors and preadipocytes following manipulation of the SNS, ARs and putative intracellular
pathway components. This dissertation is organized into two major Specific Aims, summarized
by the following questions:
SA1, Part 1: What is the impact of SNS activation on the populations and
proliferation of APCs in WAT? Evidence produced by previous studies strongly supports the
belief that the SNS regulates proliferation of WAT SVF cells (Jones, Ramsay et al. 1992,
Cousin, Casteilla et al. 1993, Foster and Bartness 2006). Researchers pointed to preadipocytes in

8

particular as being impacted by the SNS, via its principal postganglionic neurotransmitter NE. It
is now known that the methods used in these studies were, unfortunately, not truly specific to
preadipocytes, nor to any other distinct cell type found in the SVF of WAT. To address these
problems and more confidently segregate preadipocytes, as well as adipocyte progenitors, from
the heterogeneous pool of SVF cells, we designed our experiments such that our final analyses
were performed using multicolor flow cytometry. This approach to collecting data allowed us not
only to assess how individual tests changed the population count and proliferation status of
APCs, but also to identify shifts in cell viability and detect trends in the commitment of ADSCs
to the adipose lineage.
We expected to find inhibition of either adipocyte progenitor or preadipocyte, or both,
population counts and proliferative activities following SNS stimulation. We started our testing
with wild-type (WT) mice subjected to an endogenous activator of the SNS, cold exposure (4ºC)
for 7 days. Adipocyte progenitor and preadipocyte populations from IWAT of cold-exposed
mice were compared with mice housed at room temperature (RT). Follow-up experiments, which
incorporated measurement of proliferative status, were performed in vitro using primary IWAT
SVF cells from WT mice cultured and exposed to various concentrations of the SNS
neurotransmitter, NE.
SA1, Part 2: Which AR subtype does the SNS target in order to suppress WAT
hyperplasia? It is established that NE, released by sympathetic nerves, binds to ARs on
postsynaptic cells in WAT. Evidence supports the notion that, as opposed to α-ARs, the β-ARs
play a role in regulating AT growth (Geloen, Collet et al. 1988, Bronnikov, Bengtsson et al.
1999). Blocking both the β1- and β2-ARs impedes NE’s ability to inhibit proliferation in IWAT
(Jones, Ramsay et al. 1992). We therefore predicted that SNS intervention in APC proliferation
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is mediated through either or both the β1- and β2-AR. To test this prediction, we cultured
primary IWAT SVF cells from WT mice and pre-treated them with a pan-β1- and β2-AR blocker
prior to NE exposure. Next, we used selective ligands for β1- and β2-ARs independently in
culture to parse out the specific β-AR subtype facilitating NE’s anti-adipogenic effects on cells in
vitro. β-AR agonist and antagonist injections were then administered to mice housed in
thermoneutral and cold climates, respectively, to ascertain whether or not the inhibition could be
replicated in vivo where SNS stimulation was muted (thermoneutral) or enhanced (cold). For all
experiments, changes in APC populations and proliferation were measured using flow cytometry
analyses.
SA2: What are the molecular mechanisms by which the SNS inhibits WAT
hyperplasia? The experiments in SA1 assessed SNS influence over WAT hyperplasia with an
emphasis on how growth of specific cell types (here, APCs) were impacted. Testing in SA1 also
delineated the likely β-AR subtype to which NE binds in order to exert its anti-adipogenic effect.
It is the intracellular molecules downstream of the β-AR that are ultimately responsible for
inhibiting the cell’s cycle, yet putative signaling pathways involved in NE’s inhibition of WAT
adipogenesis have never before been explored. In SA2, we begin to parse out these molecular
mechanisms.
ARs are G protein-coupled receptors (GPCRs) that, once bound by a ligand, transduce a
cascade of intracellular signaling events. At times, molecules activated by such signaling
pathways include those that impact cell cycle-regulating mechanisms (Drake, Shenoy et al. 2006,
Rosenbaum, Rasmussen et al. 2009). Our search for likely intracellular players is enhanced by
knowledge of the specific AR subtype that NE interacts with to exert its inhibitory effects.
Different AR subtypes are associated with varied, sometimes opposing, cellular responses
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(Evans, Sato et al. 2010, Casella, Ambrosio et al. 2011). Here we examined the role of AMPK,
an intracellular energy-sensing enzyme complex that becomes phosphorylated and activated
downstream of β-AR stimulation. The effects of elevated AMPK include reduced protein
synthesis and cell growth (Mihaylova and Shaw 2011). We tested the involvement of AMPK in
NE’s overall anti-hyperplasia impact using a pharmacological blocker of AMPK known as
Compound C, or dorsomorphin. Cells in culture were pretreated with Compound C prior to the
addition of a specific β-AR agonist. We predicted the pretreatment with Compound C would
restore APC proliferation levels in comparison to cells treated with the β-AR agonist alone.
Changes in APC populations and proliferation were measured using flow cytometry analyses.
2
2.1

SPECIFIC AIM 1

Background
2.1.1

Adipocyte precursor cells

We hypothesize that SNS activation influences adipocyte precursor cell content and
proliferation in WAT. Adipocyte precursor cells (APCs) is a collective term for adipocyte
progenitors and preadipocytes, which are non-terminally-differentiated adipogenic cells.
Multipotent stem cells (MSCs) give rise to adipocyte progenitors upon commitment to the
adipose lineage. The maturation of MSCs to adipocyte progenitors is the first step towards
differentiation in the adipogenic pathway. Adipocyte progenitors then have the capacity to
further differentiate into preadipocytes. Preadipocytes are even further along in their adipogenic
development and can ultimately undergo terminal differentiation to become mature adipocytes,
as illustrated in Figure 1 (Berry and Rodeheffer 2013).
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Figure 1. Graphic representation of adipocyte precursor cell development.
Adipose-derived stem cells have the capacity to commit to the adipose lineage, at which
point they become adipocyte progenitors, which can further mature into preadipocytes
and ultimately into adipocytes.
Until recently, studying APCs was exceptionally challenging in large part due to the lack of a
robust technical approach for separating them from the plethora of other cell types found in the
SVF of WAT.
One method for isolating APCs relies upon the fact that preadipocytes can be
differentiated into adipocytes in vitro, and that lipid-laden adipocytes are less dense than other
cell types. In such experimental designs, the SVF, which includes preadipocytes, is cultured and
subjected to testing. To ascertain whether the tests have an effect on preadipocyte proliferation,
tritiated thymidine (3H-T) is added to the media along with the test agents. The 3H-T is a means
of radioactively labeling proliferating cells since 3H-T will incorporate into newly-synthesized
DNA. This test phase is followed by a differentiation phase, whereby the preadipocytes are
induced to mature into lipid-filled adipocytes. Cells are harvested and subjected to a Percoll
density gradient centrifugation protocol. The procedure promotes aggregation of adipocytes in
the top layer, or gradient, of solution while the remaining, denser SVF cells sink to the bottom.
Adipocytes that originated from the radioactively-labeled preadipocytes maintain the 3Hthymidine in their DNA, so in this way it is possible to locate and separate preadipocytes from

12

the heterogeneous mixture and assess effects on their proliferation (Jones, Ramsay et al. 1992,
Hausman, Park et al. 2008). This methodology is a creative approach to isolating preadipocytes
from the remaining cells in the SVF. More recently, however, it has been found that the
uppermost layer resulting from the Percoll density gradient procedure can be readily
contaminated with macrophages (Tchoukalova, Fitch et al. 2012).
A different tactic involving histological analyses has also been taken by our lab and
others. Repeated injections of bromodeoxyuridine (BrdU) label proliferating cells in rodents that
have previously undergone chemical or mechanical ablation of the nerves innervating WAT.
After WAT is harvested and sectioned, immunohistochemical staining is performed with
antibodies against both BrdU and AD3. In the past, it was thought that AD3 was a selective
surface marker for preadipocytes (Wright and Hausman 1990, Kras, Hausman et al. 1999).
Where double-labeling was found for both BrdU and AD3, these were interpreted as being
adipogenic cells whose proliferative status had been impacted by denervation (Foster and
Bartness 2006). It has been noted, however, that WAT histology is very challenging to interpret,
given that the overwhelming majority of space inside the tissue is consumed by the lipid droplets
of individual adipocytes. The interstitial space, where APCs and other SVF cells are located, is
difficult to resolve given that it is so tightly squeezed between neighboring adipocytes (Berry,
Jeffery et al. 2014). In our lab, AD3 staining appeared to lack some specificity (unpublished
observations). In summary, the Percoll gradient separation and immunohistochemical staining
are now known to be less selective for isolating APCs as compared to multicolor, multiparameter flow cytometry analyses.
To this end, we adapted and optimized a protocol to select for APCs from the
heterogeneous SVF of mouse IWAT (Church, Berry et al. 2014). We tested and fine-tuned a
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panel of seven fluorescently-conjugated antibodies directed against surface proteins that, in
combination, minimized spectral overlap and allowed us to confidently delineate APC
populations from other cell types. We later supplemented our protocol with the addition of
intracellular staining using an antibody directed against the cyclin Ki67, which is present in the
G1, S, G2 and M-phases of the cell cycle, but absent in G0 (Qu, Liu et al. 2015). In this way, we
were able to determine effects on the proliferative status of adipocyte progenitors and
preadipocytes independently of one another.

Figure 2. Flow cytometric analysis showing the progression of selecting for cells of
interest.
From one representative control mouse, these plots demonstrate our gating strategy, with
the first gate being P1, which isolates viable cells; sequential gates are created such that
only cells included in the previous gate are considered for further selection (i.e., only P1
cells are analyzed when selecting cells for the P2 gate, and so forth); P5 defines
preadipocytes while P6 defines adipocyte progenitors; P7 is a dependent of P5,
evaluating only preadipocytes for the presence of Ki67; P8 is a dependent of P6, showing
only adipocyte progenitors that are positive for Ki67.
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Flow cytometry gating for isolation of APCs is shown in Figure 2. The initial plot of
forward scatter (FSC) and side scatter (SSC) was further drilled down to select for live cells.
Cells that were negative for our viability stain, FVS700, were considered viable, as necrotic cells
allow for the diffusion of FVS700 and binding of the stain to intracellular amines whereas live
cells exclude the dye. Cells that did not stain positively for FVS700 were selected for in the P1
gate. P1 cells were next assessed for CD31 and CD45 expression (endothelial cell and
hematopoietic cell markers, respectively) and the gate P2 was drawn around cells that were
negative for these markers (CD31-: CD45-). P2 cells were further analyzed for enrichment in
CD29 (β1 integrin) and CD34, a common mesenchymal stem cell (MSC) marker and ADSC
marker, respectively (Calloni, Cordero et al. 2013, He, Duan et al. 2013). The gate P3 was drawn
around these cells (CD31-: CD45-: CD29+: CD34+). The P3 cell population was then evaluated
for the presence of CD140a, commonly known as platelet-derived growth factor receptor α
(PdgfRα). P3 cells that were positive for PdgfRα were captured in the P4 gate (CD31-: CD45-:
CD29+: CD34+: PdgfRα+). The cells in P4 were probed for Ly-6A/E and CD24 enrichment. Ly6A/E is commonly known as stem cell antigen-1 (Sca-1) and its expression is indicative of both
types of APCs (adipose progenitors and preadipocytes). The divergent factor between adipocyte
progenitors and preadipocytes is the expression of CD24 (also known as Heat-Stable Antigen).
Whereas adipocyte progenitors are enriched in CD24, preadipocytes lack CD24 expression
(Berry, Jeffery et al. 2014, Church, Berry et al. 2014).
Fluorescence minus-one (FMO) controls were used to create and confirm gating,
especially in two-color dot plots where delineation between positive and negative expression was
more challenging (for example, the division between P5 and P6, both of which select for Sca1+
cells but differentiate between CD24- and CD24+). FMO controls were those in which a sample
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was stained with all antibodies except for one. A separate FMO control was prepared for each
antibody and, in each case, the one antibody that was missing was considered to be the antigen of
interest. The FMO control was compared to a sample that had been exposed to all antibodies
(Figure 3).

Figure 3. Representative FMO control for CD24 (FMO-CD24).
Cells from one mouse were divided such that a portion were exposed to every antibody
with the exception of the antigen of interest, CD24 (left plot) while the other portion was
stained as per usual with all antibodies (right plot).
As long as compensation had been calculated correctly, there were no positive events appearing
for the antigen of interest in the FMO control sample, whereas there were positive events for the
antigen of interest in the analysis of cells stained with all antibodies.
Specifically, the FMO control for CD24 (FMO-CD24) consisted of cells incubated in all
fluorescent compounds (FVS700, FITC-CD29, PE-Cy7™ -CD31, Alexa Fluor® 647-CD34,
APC-Cy7™-CD45, BV421-CD140A, BV605-Ly-6A/E and PE-Ki67) with the exception of
BV510-CD24. The antigen of interest for FMO-CD24 was CD24. Where compensation had been
sufficiently calculated, the specific antibody that was missing (here, CD24) only showed
negative events in its dot plot. In addition to help with drawing gates, this technique allowed for
greater confidence in interpreting positive events as being attributable to the presence of the

16

antigen of interest rather than due to spectral overlap with other fluorophores (Church, Berry et
al. 2014).
As our technical skills advanced, we added a permeabilization step such that we could
measure changes in levels of Ki67, an intracellular marker of proliferation. The two APC cell
types could then be individually examined for impacts on proliferation, with Ki67 staining for
preadipocytes shown in the gate P7 (CD31-: CD45-: CD29+: CD34+: PdgfRα+: Sca1+: CD24-:
Ki67+) and adipocyte progenitors in P8 (CD31-: CD45-: CD29+: CD34+: PdgfRα+: Sca1+:
CD24+: Ki67+).
2.1.2

Adrenergic receptors

We hypothesize that SNS regulation of WAT hyperplasia is facilitated through
stimulation of either or both of the β1- and β2-ARs. SNS-released catecholamines, including NE,
bind to α- and β-ARs expressed on the plasma membranes of cells in their target tissues. In
WAT, α- and β-ARs have contradictory effects on lipolysis, with α2-AR signaling being antilipolytic while β-AR activation drives lipolysis (Langin 2006). The specific AR(s) with which
NE interacts to ultimately suppress APC proliferation has yet to be fully characterized in the
literature. From previous research, however, it appears likely that NE binds to and activates one
or more of the β-ARs to inhibit WAT hyperplasia. Defining the particular β-AR(s) mediating the
effects of the SNS is of interest because different subtypes, as well as different ligands binding to
these subtypes and the cell type on which the β-AR subtype is expressed, are known to elicit
unique intracellular signaling events (Evans, Sato et al. 2010). To translate this research for use
in a clinical setting, ensuring patient safety to the greatest extent possible, it is necessary for us to
understand the precise mechanisms directing the inhibition of hyperplasia.
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2.2

Methods
2.2.1

Animals

C57BL/6J male mice (The Jackson Laboratory, Bar Harbor, ME) were used for all
experiments. Mice were acclimated to the vivarium for a minimum of three days prior to the start
of a cold exposure experiment, and for 3 weeks prior to the start of an experiment conducted in
thermoneutral conditions. Mice were aged five to seven weeks at the start of each experiment.
The animal studies were approved by the institutional animal care and use committee of Georgia
State University. All animals were housed in temperature-controlled facilities with a 12-hour
light/dark cycle and free access to normal chow diet (LabDiet, St. Louis, MO; Purina #5001) and
water.
2.2.2

Tissue harvest and isolation of stromal vascular fraction

Bilateral IWAT depots were harvested from mice. The IWAT was processed following the
methodology of Hausman, et al. (Hausman, Park et al. 2008). Collagenase type 1 (Worthington
Biochemical Corp., Lakewood, NJ; cat. #CLS-1) prepared in HEPES buffer (final
concentrations: 0.1M HEPES, 0.12M NaCl, 50mM KCl, 5mM D-glucose, 1.5% bovine serum
albumin, 1mM CaCl2) was used for the tissue digest. Tissue was digested for ~45-60 minutes in
a shaking water bath. A series of filtration and centrifugation steps followed the digest such that
the SVF was sufficiently separated from mature adipocytes. The floating adipocyte layer was
removed and discarded. After sufficient suspension of the SVF pellet in media, an aliquot was
taken and further mixed in trypan blue solution 0.4% (GIBCO Laboratories, Gaithersburg, MD;
cat. #15250). SVF cells were counted using the Cellometer Auto 2000 cell viability counter
(Nexcelom, Lawrence, MA).
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2.2.3

Flow cytometry analyses

For cell staining, fixable viability stain 700 ((FVS 700) BD Biosciences, San Jose, CA;
cat. #564997) was added at a concentration of 1:500 to each tube, followed by vortexing then
incubation at RT for 15 minutes. To each tube, 2 mL of FACS buffer (D-PBS with 2mM EDTA
and 0.5% bovine serum albumin) was added and cells were centrifuged for 5 minutes at 1500
rpm. The supernatants were decanted and the FACS buffer wash step repeated. To each tube,
0.05 mL of FACS buffer was added along with 2 uL of Mouse BD FcBlock (cat. #553142) and
cells were incubated for 30 minutes on a rotator at 4°C. Surface stains in 0.05 mL Brilliant Stain
Buffer (cat. #563794) were added next and cells were typically incubated in these stains
overnight on a rotator at 4°C. The seven antibodies used to target surface antigens were as
follows: BV510 Rat Anti-Mouse CD24 (cat. #563115), FITC Hamster Anti-Mouse CD29 (cat.
#555005), PE-Cy7™ Rat Anti-Mouse CD31 (cat. #561410), Alexa Fluor® 647 Rat Anti-Mouse
CD34 (cat. #560233), APC-Cy7™ Rat Anti-Mouse CD45 (cat. #557659), BV421 Rat AntiMouse CD140A (cat. #562774) and BV605 Rat Anti-Mouse Ly-6A/E (cat. #563288). All
surface antibodies and stain buffers were purchased from BD Biosciences. Surface antibodies
were used at concentrations of 1:100 with the exception of Anti-Mouse CD31 and Anti-Mouse
CD45, which were used at a concentration of 1:200.
Cells were fixed using a working solution of Fix/Perm Buffer then permeabilized with a
working solution of Perm/Wash Buffer. Both buffers were provided in BD Pharmingen’s
Transcription Factor Buffer Set (cat. #562574). PE Anti-Mouse Ki67 was the intracellular stain
used to assess proliferation (BioLegend, San Diego, CA; cat. #652404) at a concentration of
1:200. PE Anti-Mouse Ki67 was added to the cells in 1x Perm/Wash Buffer followed by
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incubation of ~1 hour. Samples were washed and prepared for analyses by resuspending in
FACS Buffer.
Unstained and single-stained cells were used as controls. They were also used, along with
single-stained compensation beads (BD Biosciences; cat. #552845) as needed, to set voltages and
calculate compensation. FMO controls were prepared to confirm accurate compensation and to
assist in drawing gates. Cells were analyzed on a BD LSRFortessa™ flow cytometer using BD
FACSDiva™ software.
2.2.4

Cell culture protocol

Cells were seeded at a density of ~1.3 x 104 cells/cm2 in 6-well tissue culture plates
(Corning, Inc., Corning, NY; cat. #353046). The day on which the cells were plated was termed
“Day 0”. On Day 0 cells were inoculated in “plating medium”, which consisted of Dulbecco’s
Modified Eagle Medium (DMEM)/F-12 media (GIBCO; cat. #11330) supplemented with 10%
fetal bovine serum (FBS) and 1% L-Glutamine/Streptomycin/Penicillin ((antibiotics) Sigma
Aldrich, St. Louis, MO; cat. #G6784). Media was removed and replaced with fresh plating
medium on day 1. On day 3 the media was replaced with “low serum medium”, which consisted
of DMEM/F-12 without phenol red (GIBCO; cat. #11039) containing 1% antibiotics and 1%
FBS media.
The test period was initiated when the cells were ~70% confluent, which typically
occurred on day 4, and testing lasted for ~48 hours. This period consisted of cells being exposed
to test compounds first prepared in appropriate vehicles (water or organic solvent) then diluted in
DMEM/F-12 supplemented with 1% FBS. Test compounds were ligands or blockers of ARs and
included the pan-AR ligand L-(-)-Norepinephrine (+)-bitartrate salt monohydrate ((NE) cat.
#A9512), propranolol hydrochloride (dual β1 and β2-AR antagonist; cat. #P8688), CGP-20712A
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(specific β1-AR antagonist; cat. #C231), ICI-118551-hydrochloride (specific β2-AR antagonist;
cat. #I127), dobutamine hydrochloride (selective β1-AR agonist; cat. #D0676) and salbutamol
(selective β2-AR agonist; cat. #S8260). When cells were exposed to a pre-treatment with
antagonists or inhibitors prior to adding agonists or activators, the pre-treatment lasted for ~1
hour. All test compounds were purchased from Sigma Aldrich. After the test period concluded,
cells were first washed with 1X Dulbecco’s phosphate buffered saline ((D-PBS) Corning; cat.
#21-031-CV) followed by the addition of Accutase® cell detachment solution (Innovative Cell
Technologies, Inc., San Diego, CA; cat. #AT-104-60). Cells were left to incubate for dissociation
up to 1 hour at room temperature (RT) in Accutase®. After gentle mechanical detachment, the
contents of each well were aspirated into its own round-bottom 12 x 75-mm polystyrene tube
(Corning; cat. #352052). Tubes were centrifuged in a swing-bucket centrifuge at RT for 5
minutes at 1400 rpm. The Accutase® supernatant was removed and the pellets resuspended in
0.1 mL 1X D-PBS.
2.2.5

Statistics

Data were analyzed using Microsoft Excel 2017 and are presented as means with error bars
expressed as ± standard error of the mean (s.e.m.). Statistical analyses were performed using IBM
SPSS Statistics 20 software. For comparisons between two independent samples, t-tests were run
for parametric data while the Kolmogorov-Smirnov Z-test was run for nonparametric data.
Experiments with larger sample sizes were analyzed using One-Way ANOVA and the appropriate
post-hoc tests. Differences were deemed statistically significant with p<0.05.
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2.3

Results
2.3.1

Cold exposure inhibits APC populations

Prolonged exposure to cold temperatures is an established stimulator of the SNS (HimmsHagen 1967). To test our hypothesis that activation of the SNS inhibits APC populations, we
exposed mice to the cold (4oC) for seven days. One group of mice was housed at room
temperature (RT) while another was housed in a cold box (4°C). IWAT from each mouse was
harvested and processed for flow cytometry analysis.
Preadipocyte population of mice held at RT for seven days was 9.08% while that of mice
housed at 4°C was significantly reduced at 4.00% (Fig. 4A). Adipocyte progenitor cell
populations also were reduced in mice housed at 4°C (1.30% vs. 4.40% in RT mice; Fig. 4B).

Figure 4. Cold exposure inhibits APC populations.
Preadipocyte (A) and adipocyte progenitor (B) cell populations in mice kept at RT
(n=11) or challenged with cold exposure (n=10) for 7 days.
Taken together, these results suggest that activation of SNS by prolonged cold exposure inhibits
both adipocyte progenitor and preadipocyte content in IWAT.
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2.3.2

Norepinephrine inhibits preadipocyte proliferation likely via activation of β1-

adrenergic receptors
Because NE is the principal neurotransmitter released by sympathetic nerves, we next
sought to determine the role of NE in APC proliferation. We tested NE’s impact using primary
cell culture of mouse IWAT SVF cells. Cells were treated with NE in concentrations ranging
from 1nM-10µM for 2 days. Neither adipocyte progenitor nor preadipocyte population counts
were changed by NE exposure, though preadipocyte population had a tendency to be reduced by
1µM NE (Fig. 5A-B). In terms of proliferation, however, cells treated with 1µM NE had reduced
preadipocyte proliferation at 6.47% as compared with controls at 10.11% (Fig. 5D). No effects
were seen with other concentrations of NE nor was there any change in adipocyte progenitor
proliferation (Fig. 5C).
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Figure 5. Norepinephrine inhibits preadipocyte proliferation through the β1 or β2adrenergic receptor.
Adipocyte progenitor populations (A), preadipocyte populations (B), proliferating
adipocyte progenitors (C) and proliferating preadipocytes (D) after 2 days of treatment
with norepinephrine (NE), with or without propranolol (prop) pre-treatment, where
p=0.047 comparing NE 1µM to control (Ctrl) without propranolol (basal control); each
column is the mean of n=4-6 cell culture wells per treatment.
To determine which β-AR subtype mediates NE’s inhibitory effect, we first tested
propranolol, a β1- and β2- AR antagonist, because previous research implicates SNS regulation
of AT proliferation through these β-ARs in WAT and brown AT (BAT) (Jones, Ramsay et al.
1992, Bronnikov, Bengtsson et al. 1999, Lee, Petkova et al. 2015). Cells pretreated with 5µM
propranolol prior to the addition of 1µM NE restored preadipocyte proliferation to control
without propranolol (basal control) levels (Fig. 5D). Propranolol pretreatment of cells without
NE, or exposed to other concentrations of NE, tended to increase preadipocyte proliferation but
the difference was not significant when compared to basal control. Propranolol did not alter the
impact of NE on adipocyte progenitors (Fig. 5C). Blocking the β1- and β2-ARs seems to rescue
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the inhibitory effect of NE, implying that NE acts through the β1- or β2-AR to hinder
preadipocyte proliferation in WAT.
To further distinguish between the β1- and β2-ARs, we treated cells for 2 days with the
selective β1-AR agonist, dobutamine hydrochloride, or the selective β2-AR agonist, salbutamol,
in doses ranging from 100nM to 10µM. Dobutamine hydrochloride at the concentrations of 1µM
and 10µM significantly inhibited both population counts and proliferation of preadipocytes.
Preadipocyte populations were 26.01% and 23.47% for cells exposed to dobutamine 1µM and
10µM, respectively, as compared to controls at 34.17% (Fig. 6B). Proliferation of preadipocytes
was measured at 25.38% and 22.54% of live cells versus controls at 33.66% (Fig. 6D).
Adipocyte progenitor populations and proliferation trended to be downregulated by dobutamine
10µM but results were not significant (Fig. 6A, 6C).
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Figure 6. The β1-AR agonist dobutamine inhibits preadipocyte population and
proliferation.
Adipocyte progenitor (A) and preadipocyte populations (B), and adipocyte progenitor (C)
and preadipocyte proliferation (D) following 2 days of treatment with dobutamine (Dob)
versus controls (n=6 cell culture wells per treatment); *p<0.05 vs. Control.

In contrast, salbutamol at the same concentrations had essentially the opposite effect.
Both populations and proliferation of preadipocytes increased, with population counts again
being almost equivalent to the number of proliferating cells (populations not shown; Fig. 7B).
Whereas proliferating preadipocytes in vehicle-treated controls accounted for 24.99% of live
cells, the percentages of proliferating preadipocytes were increased to 32.81% of cells exposed to
1µM salbutamol and 32.60% of cells exposed to 10µM salbutamol. Numbers of preadipocytes
were also stimulated by salbutamol, with the preadipocyte population accounting for 33.48% and
33.45% of live cells in the 1µM and 10µM salbutamol groups, respectively, as compared to
26.07% of live cells in the control group (data not shown). Adipocyte progenitor population and
proliferation trended upwards by salbutamol treatment but was not significant (populations not
shown; Fig. 7A).
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Figure 7. The β2-AR agonist salbutamol promotes preadipocyte population and
proliferation.
Proliferating adipocyte progenitors (A) and preadipocytes (B) following 2 days of
treatment with salbutamol (Salb) versus controls (n=6-10 cell culture wells per
treatment); *p<0.05 vs. Control.
These data support a role of the β1-AR in mediating inhibitory effects on IWAT
preadipocyte hyperplasia in vitro. Conversely, activation of the β2-AR appears to promote
hyperplasia in vitro.
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2.3.3

The sympathetic nervous system inhibits preadipocyte proliferation through the

β1-adrenergic receptor in vivo
We next conducted in vivo experiments to further test our hypothesis that β1-AR
activation propagates the intracellular signaling that disrupts APC proliferation. We began with a
cold exposure experiment in which one group of mice received daily 3mg/kg intraperitoneal (ip)
injections of the selective β1-AR antagonist, CGP 20712A, while a control group was injected
with an equivalent volume of saline. All mice were housed at ~5°C for one week. We anticipated
blockade of the β1-AR to reverse the inhibition of proliferation we expected to see in control
mice.
Differences between the two groups trended towards meeting our expectations for
preadipocytes but were not robust enough to be significant (21.47% vs. 20.65% for control mice;
Fig. 8B). In analyzing effects of the antagonist on adipocyte progenitor proliferation, the data
interestingly trended in the opposite direction of preadipocytes. Antagonist-injected mice had
slightly reduced percentages of proliferating adipocyte progenitors in comparison to salinetreated mice, but differences again were not significant (9.88% vs. 11.47% for control mice; Fig.
8A). No differences were apparent when comparing population counts of the two groups of mice
for either adipocyte progenitors or preadipocytes (data not shown).
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Figure 8. The β1-AR antagonist CGP20712A has no impact on APC proliferation
when administered at 3mg/kg/day in cold-exposed mice.
Proliferating adipocyte progenitors (A) and preadipocytes (B) following 7 days of
CGP20712A injections combined with cold exposure (n=4 mice per group).

Our belief is that deviations were minimal in part because cold exposure on its own is a
major metabolic challenge and because the dose of CGP 20712A was relatively conservative.
We decided to take an alternate approach to in vivo testing of the β1-AR by eliminating
the cold challenge and stimulating, rather than impeding, the β1-AR signaling cascade. We again
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chose dobutamine to selectively activate the receptor. We housed the mice at RT and
administered ip injections at a modest daily dose (1mg/kg) for one week, with control
counterparts being given saline injections (Miura, Kawanaka et al. 2007). We expected
stimulation of the β1-AR to suppress adipogenesis as compared to control mice.
Again, the data trended towards meeting our expectations but were not significant. For
preadipocytes, dobutamine reduced proliferation to 31.05% of live cells vs. 38.40% in vehicleinjected mice (Fig. 9B). Adipocyte progenitor proliferation was extremely small and the
variation between the groups did not reach significance (0.17% in dobutamine-treated mice
versus 0.25% for control mice; Fig. 9A), though this was not significant.
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Figure 9. Dobutamine has no impact on APC proliferation when administered at
1mg/kg/day in RT-housed mice.
Proliferating adipocyte progenitors (A) and preadipocytes (B) following 7 days of
dobutamine injections at RT (n=4 mice per group).

Ambient RT (~22oC) can present a mild cold challenge and we had chosen a more
moderate dosage for the dobutamine injections (Malo and Puerta 2001). We decided to proceed
by increasing the concentration of dobutamine while maintaining the animals in an environment
that would minimize baseline sympathetic tone to WAT.
We injected dobutamine at 10mg/kg daily for one week and repeated the equivalent
volume of saline for controls (Fig. 10). All animals were housed in thermoneutral (TN)
conditions (30°C) to minimize the potential inhibitory effect of cold stress on cell proliferation
(Cannon and Nedergaard 2011, Kalinovich, de Jong et al. 2017, van der Stelt, Hoevenaars et al.
2017). We predicted that, as we saw with our in vitro experiments using dobutamine, APC
proliferation would be inhibited in those mice that received ip injections of dobutamine as
compared to controls. Indeed, we saw significant inhibition of preadipocyte proliferation in the
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mice injected with dobutamine in comparison with controls (8.57% vs. 22.69% for salineinjected mice; Fig. 10B). Adipocyte progenitor proliferation also was significantly reduced in
dobutamine-injected mice in comparison to controls (1.13% vs. 3.18% for saline-injected mice;
Fig. 10A). Populations of both cell types were almost equivalent to their corresponding
percentages of proliferating cells, and were also significantly reduced by dobutamine
administration (data not shown).
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Figure 10. Dobutamine inhibits APC proliferation when administered at 10
mg/kg/day in thermoneutral-housed mice.
Proliferating adipocyte progenitors (A) and preadipocytes (B) following 7 days of
dobutamine injections (n=5) versus controls (n=7); *p<0.05 vs. Vehicle.

The combined in vitro and in vivo data strongly support our assertion that NE released by
SNS nerves inhibits WAT preadipocyte hyperplasia via the β1-AR.
2.4

Summary of Specific Aim 1
Previous studies have examined SNS regulation of WAT hyperplasia using different

techniques to select for APCs from the heterogeneous SVF, but these applications have since
been determined to be less accurate and robust in comparison to multicolor flow cytometry.
Essentially, to examine effects on adipogenic cells specifically, it is necessary to separate these
cells from the remaining components of AT. Other cells found in AT include, but are not limited
to, blood and endothelial cells, immune factors, MSCs, and neurons.
To enrich for APCs explicitly and identify changes in proliferative activity, we adapted a
protocol using antibodies against seven surface markers and added intracellular staining of Ki67,
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a protein present only in the active phases of the cell cycle. Both adipocyte progenitor and
preadipocyte populations were diminished in the repeated in vivo cold-exposure experiments.
Activation of the β1-AR via dobutamine in vivo or in vitro decreased both progenitor cell and
preadipocyte proliferation, mimicking the inhibitory effect of SNS activation on APC contents.
In contrast, the β2-AR agonist, salbutamol, increased preadipocyte proliferation in vitro. The
opposite effect of β1- and β2-ARs may explain our observation in the in vitro experiment in
which NE treatment only inhibited preadipocyte proliferation but not progenitor cells. Adipocyte
progenitors may have altered expression of the β2-ARs, activation of which potentially offset the
activation of β1-ARs by NE that binds to all AR subtypes. Our data indicate that the β1-AR
likely mediates the inhibitory effect of SNS activation on APC contents and proliferation.
Changes in adipocyte progenitor percentages were at times dissimilar, though overall
adipocyte progenitors were not impacted by our tests in general. Adipocyte progenitor
population and proliferation levels varied in our cold exposure experiments. It is of note that
adipocyte progenitors consistently accounted for a much smaller fraction of APCs as compared
to preadipocytes. As mice age, marked development of adipocyte progenitors into preadipocytes
has been reported elsewhere in the literature (Berry and Rodeheffer 2013). With preadipocytes
being more enriched and further along in the differentiation process than adipocyte progenitors,
effects on preadipocytes are perhaps more relevant to our goal of understanding the antiobesogenic mechanisms of the SNS.
When preadipocyte content or proliferation was inhibited in vivo, this was accompanied
by a significant reduction in adipocyte progenitor content or proliferation. Interestingly, when
preadipocyte proliferation was significantly impacted in vitro, adipocyte progenitor proliferation
did not change. Evaluating the in vitro results in particular could point to the SNS having the
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ability to discourage differentiation of adipocyte progenitors and their further commitment to the
adipose lineage by developing into preadipocytes. This was not the case with our in vivo results,
however, which may be better interpreted as the SNS curtailing cell cycle events in APCs as a
whole. From our in vivo experiments, it seems the SNS imparts a growth arrest effect on APCs,
prompting both adipocyte progenitors and preadipocytes to halt their progression towards DNA
replication and, ultimately, cell division.
3
3.1

SPECIFIC AIM 2

Background
3.1.1

The cell cycle

We hypothesize that the SNS directs APC cell cycle activity through manipulation of
AMPK. Hyperplasia, or proliferation, is the process in which new cells are created from existing
cells. To accomplish this, existing cells participate in a series of ordered events, collectively
termed the cell cycle. In brief, these events include the generation of additional proteins and
organelles, synthesis of exact copies of its deoxyribonucleic acid (DNA), delivery of these copies
correctly into two new nuclear envelopes and division of the cytoplasm such that two identical
daughter cells are formed. A cell which is not terminally differentiated, such as an APC, has the
capacity to enter into the cell cycle. The term adipogenesis is used exclusively to indicate
proliferation of APCs, resulting in the formation of new adipocytes.
Adipogenesis occurs when adipocyte progenitors and preadipocytes leave the resting
state, known as G0, and enter into the active phases of the cell cycle. The first of these phases is
G1 and it is the period in which a cell begins to duplicate its cytoplasmic components, such as
organelles and proteins. Fairly late in G1 there is a checkpoint, known as the “restriction point” in
mammals. Procession past the restriction point is an irreversible commitment to DNA
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duplication. When a healthy cell in G1 receives communication that external conditions are
unfavorable, and if it has yet to pass the restriction point, it has the capacity to stop advancing
and revert back to G0. Provided the cell passes the G1 restriction point, the S-phase is the next
stage that ensues. S-phase entails synthesizing copies of the existing cell’s two chromosomes,
resulting in two pairs of identical chromosomes. The G2 segment of the cell cycle involves more
preparation for cell division, with regulatory steps being taken to ensure proteins are not
misfolded and DNA has been properly replicated. After G2 the cell enters into the M-phase, or
mitosis. Mitosis includes several steps for accurate segregation of the chromosomes into two
newly-formed nuclei, each being intended for the resulting two daughter cells. Division of the
cytoplasm and formation of new plasma membranes occurs in cytokinesis, the final procedure.
The protein Ki67 is expressed during all phases with the exception of G0. The
measurement of Ki67 levels is commonly used as an indicator of a cell’s proliferative activity.
An intervention that reduces Ki67 expression can be interpreted, therefore, as one in which cells
received extracellular signals warning them of an environment that was not optimal for
replication, prompting them to remain in or return to the resting state of G0.
3.1.2

Cell cycle control

Intracellular regulatory proteins are responsible for instructing cells to engage in or
refrain from cell cycle events. Specific regulatory molecules that control cell cycle progression
include cyclin-dependent kinases (Cdks) and cyclins. Cdks help advance the cell cycle by
phosphorylating other molecules that promote proliferation. In order to become active, however,
Cdks must first be bound by proteins known as cyclins, forming a Cdk-cyclin complex. The
complex is then phosphorylated by Cdk-activating kinases (CAKs) to become fully activated.
Cdks are expressed at a relatively constant rate inside the cell while cyclin levels fluctuate.
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Different Cdk-cyclin complexes are present during the various phases of the cell cycle
(Suryadinata, Sadowski et al. 2010).
A point of regulation at the beginning of cycle occurs when cyclin D binds with either
Cdk4 or Cdk6 to promote movement from the G1 phase, past the restriction point, into S-phase
(Shapiro 2006, Hamilton and Infante 2016). Cdk4/6 phosphorylates the retinoblastoma protein
(Rb) which triggers dissociation of Rb from E2 family (E2F) transcription factors. E2F
transcription factors are silenced when bound by Rb, but once freed are capable of translocating
to the nucleus where they facilitate DNA replication. Another Cdk-cyclin complex, Cdk2-cyclin
E, also participates in the phosphorylation of Rb in this early stage of the cell cycle, enhancing
the subsequent activation of E2F transcription factors (Anscombe, Meschini et al. 2015).
Inhibition of Cdk4/6 and Cdk2 or degradation of cyclins D and E, therefore, have the potential to
perturb entry into the cell cycle.
Cdk inhibitory proteins (CKIs) interact with Cdk-cyclin complexes and influence their
functionality, at times leading to inactivation of the Cdk-cyclin dimer. CKIs are widely used by
cells to exert control over the cycle. CKIs that function to halt progression past the restriction
point, in particular, in G1 include p21 and p27 (Besson, Dowdy et al. 2008). With regard to p27,
research demonstrates that AMPK directly phosphorylates and activates p27, enhancing its
stability and prohibiting continuation of cell cycle events past the G1 phase (Liang, Shao et al.
2007, Theriau and Connor 2017). AMPK also perpetuates the p53/p21Cip1 or Skp2 pathways.
Both the p53/p21Cip1 and Skp2 pathways ultimately inhibit proliferation (Lin, Ou et al. 2015).
3.1.3

The β1-adrenergic receptor signaling cascade and the cell cycle

In this work, we have shown that signaling through the β1-AR mediates the antihyperplastic effects of NE. Our interest extends to the likely effector proteins inside the cell that
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are upregulated after NE binds to the β1-AR. The classical sequence of intracellular events
following activation of the receptor begins with a conformational change in the G-protein
associated with the β1-AR. Of the various types of G-proteins, it is generally thought that the Gs
subtype, which targets adenylate cyclase (AC), is activated. Specifically, the α subunit of the Gs
protein (Gαs) is mobilized. AC catalyzes the conversion of adenosine triphosphate (ATP) to
cyclic adenosine monophosphate (cAMP), after which cAMP binds to and activates cAMPdependent protein kinase A (PKA).
PKA has the capacity to phosphorylate liver kinase b1 (LKB1), which then directly
phosphorylates AMPK, promoting its activation (Egan, Shackelford et al. 2011). Alternatively,
PKA can phosphorylate L-type calcium channels, which then open to allow calcium to enter the
cell. An increase in intracellular calcium concentration stimulates calcium/calmodulin dependent
protein kinase kinase 2 (CAMKK2) (Rosenbaum, Rasmussen et al. 2009). Like LKB1,
CAMKK2 is a kinase that phosphorylates AMPK at its threonine residue Thr 172 (Collins 2011).
In addition to its characteristic hindrance of anabolic pathways, AMPK activation induces
upregulation of CKIs such as p21 and p27 (Liang, Shao et al. 2007, Lin, Ou et al. 2015, Theriau
and Connor 2017).
It is plausible that p21 is an important player in NE’s perturbation of WAT hyperplasia
since previous research has implicated increased p21 levels in suppressing mitotic clonal
expansion of preadipocytes (Nam, Lee et al. 2008). It is more commonly thought that p21 is
recruited to prohibit progression through the cell cycle as a result of DNA damage, however
(Sherr and Roberts 1999). A role for p27 in WAT hyperplasia is conceivable given that p27 is
directly impacted by AMPK and AMPK activation is a clear target of messengers stimulated by
Gαs.
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We began assessing these putative intracellular mediators by testing AMPK’s
involvement. We pretreated primary cells in culture with Compound C, an AMPK inhibitor,
prior to the addition of dobutamine (Tang, Williams et al. 2011). We reasoned that, if Compound
C negates the effects of β1-AR stimulation and restores proliferation to its basal levels, then we
can reasonably suspect that AMPK is a component in the pathway elicited by NE.
3.2

Methods
The methods used to conduct tests for SA2 are identical to those used for SA1. Animals

were also male C57BL/6J mice, the tissue harvest and SVF isolation were carried out as
described above, as were the staining of cells and flow cytometry analyses. Compound C was
purchased from Tocris Bioscience (Avonmouth, Bristol, United Kingdom; cat. #3093) and
solubilized in dimethyl sulfoxide. Pre-treatment of cells with Compound C lasted ~1 hour prior
to the addition of dobutamine. Statistical testing was performed as described for SA1. The
experimental approach entailed using primary cell culture only; in vivo studies were not included
in this aim.
3.3

Results
3.3.1

The sympathetic nervous system may act through AMPK to inhibit preadipocyte

proliferation
We cultured SVF cells from mouse IWAT and repeated our testing with dobutamine. We
added a pretreatment step by exposing the cells to Compound C, a pharmacological inhibitor of
AMPK. We expected to find inhibition of proliferation once again in cells receiving dobutamine.
In addition, we anticipated that blockade of AMPK prior to dobutamine exposure restores APC
proliferation.
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In accordance with our previous testing of APCs in vitro, dobutamine hydrochloride at a
10µM concentration significantly inhibited proliferation of preadipocytes at 6.51% of live cells
versus controls at 9.71% (Fig. 11B) and had no effect on adipocyte progenitors (Fig. 11A).
Differing from prior results, dobutamine 1µM had no impact on preadipocyte proliferation.

Figure 11. The β1-AR agonist dobutamine inhibits preadipocyte proliferation.
Adipocyte progenitor (A) and preadipocyte proliferation (B) following 2 days of
treatment with dobutamine (Dob) versus controls (n=5-6 cell culture wells per treatment);
*p<0.05 vs. Control.
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Populations of both cell types were almost equivalent to their corresponding percentages
of proliferating cells, with preadipocyte content being reduced but adipocyte progenitor content
remaining unchanged by dobutamine administration (data not shown).
Adding Compound C (CC) to the cells in culture did not impact their overall viability, as
measured by FVS700 uptake, nor did CC alter the percentage of Lineage-negative cells (Lin-;
CD31-: CD45-). CC did, however, begin to diverge from controls at the level of Lin- cells, which
were further enriched with CD29 and CD34. Percentages of CD31-: CD45-: CD29+: CD34+
were diminished in comparison to controls (data not shown). APCs are Pdgfrα+ and Sca1+ in
addition to being CD31-: CD45-: CD29+: CD34+. It is understandable, then, that significantly
lesser percentages of APC populations and proliferation were calculated in cells treated with CC.
Interestingly, CC demoted adipocyte progenitor proliferation to a consistent level regardless of
the concentration of CC (Fig. 12A), while it impacted preadipocyte proliferation in a dosedependent manner (Fig. 12B).
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Figure 12. The AMPK inhibitor Compound C diminishes APC proliferation.
Adipocyte progenitor (A) and preadipocyte proliferation (B) following 2 days of
treatment with Compound C (CC) versus controls (n=5-6 cell culture wells per
treatment); *p<0.05 vs. Control.
In adipocyte progenitors, dobutamine did not initially change proliferation relative to
untreated cells and this lack of an effect persisted when cells were pretreated with CC 200nM
(Fig. 13A). With preadipocytes, dobutamine 10µM diminished proliferative activity in
comparison to untreated cells. Blocking AMPK by pretreating cells with CC, then adding
dobutamine, did not fully restore proliferation to the level of untreated cells (Fig. 13B). That
being said, preadipocytes administered dobutamine 10µM suppress proliferative activity when
compared with preadipocytes receiving basal media. In contrast, exposing preadipocytes to
dobutamine along with CC enhances proliferation in comparison to CC treatment alone (Fig.
13C).
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Figure 13. Dobutamine possibly inhibits preadipocyte proliferation through
activation of AMPK.
Adipocyte progenitor (A) and preadipocyte proliferation (B) after 2 days of treatment
with dobutamine (dob), with or without Compound C 200nM (CC) pre-treatment, and
percent change in preadipocyte proliferation compared to relevant basal controls (C);
each column is the mean of n=5-6 cell culture wells per treatment; *p<0.05 Dob 10µM
vs. Control without CC.
There were no differences in the two higher doses of CC when comparing CC-treated
cells with cells receiving both CC and dobutamine. Interpreting the data derived from CC 200nM
trials is less clear and merits further investigation into a possible role for AMPK in mediating
dobutamine’s inhibition of preadipocyte proliferation.
3.4

Summary of Specific Aim 2
We hypothesize that NE’s interaction with the β1-AR increases lipolysis followed by an

increase in the phosphorylation and activation of AMPK, a major cellular energy status sensor.

46

We found that pre-treating cells in culture with 200nM CC prior to adding dobutamine 10µM
rescues the inhibition of preadipocyte proliferation seen with dobutamine 10µM alone.
If compared directly to the proliferation levels of cells treated with dobutamine 10µM
alone, it appears as though the combination of CC and dobutamine decreases preadipocyte
proliferation. Another, perhaps more accurate means of assessing for an effect is by comparing
changes in one group of cells to its most relevant basal levels, and this rationale is supported in
the literature (Wang, Sato et al. 2014). Here, CC added to the media alone inhibits APC
population counts and proliferation. This condition, then, is the appropriate basal level to which
we compare proliferation of cells administered dobutamine following pretreatment with CC. In
first blocking AMPK then adding dobutamine, results differ from those in which cells receive the
AMPK inhibitor alone. We present repeated evidence of dobutamine’s inhibitory effect on
preadipocyte proliferation in vitro. If dobutamine were acting through an intracellular effector
other than AMPK, we could expect even greater inhibition of proliferation than that seen with
CC alone. In contrast, dobutamine administration reverses the trend, and proliferation is
enhanced in comparison to CC-treated cells. We find the same trend with adipocyte progenitors,
though the initial treatment with dobutamine did not inhibit adipocyte progenitor proliferation.
4

DISCUSSION

Obesity is a disease that conveys great physical, psychological and economic burden to the
worldwide population. Much work has been done to mitigate these effects including, but not
limited to, public health campaigns, biomedical research to enhance our understanding of the
molecular basis of the disease, and clinical research to test pharmacological and surgical
interventions. In spite of these broad efforts, the prevalence of obesity has not changed
drastically. In addition, the disease that once appeared to be isolated to developed countries has
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more recently expanded to developing nations, such that our efforts to control and contain the
problem are challenged even further (Lopes, Correa-Giannella et al. 2016). Excessive increases
in WAT mass, through an increase in the size of existing adipocytes and the number of
adipogenic cells, promotes progression towards obesity (Fernandez, Acuna et al. 2010).
Mechanisms by which WAT cell number is controlled may be key to uncovering means by
which obesity can be reversed.
4.1

Sympathetic nervous system activation and adipose tissue function
Both physiological and neuroanatomical evidence of SNS innervation of AT is now well

defined (Niijima 1989, Youngstrom and Bartness 1995, Bartness and Bamshad 1998, Nguyen,
Barr et al. 2017). AT metabolic function is known to be highly influenced by the activation of
SNS nerves synapsing with cells in the tissue. SNS-released catecholamines, including NE and
epinephrine, stimulate or inhibit the breakdown of TGs (lipolysis) in WAT via β-ARs and α2ARs, respectively (Langin 2006). In response to cold exposure, SNS drive and subsequent NE
release from nerve terminals mediates the potent induction of thermogenesis in both BAT and
WAT (Whittle, Relat-Pardo et al. 2013). NE binds to β-ARs expressed by adipocytes, and
initiates an intracellular signaling cascade that ultimately promotes synthesis of uncoupling
protein 1 (UCP1), which facilitates dissipation of energy through heat (Kalinovich, de Jong et al.
2017). Regulation of AT lipolysis and thermogenesis by the SNS have been well characterized.
Furthermore, in the quest to find antidotes to the obesity epidemic, mechanisms underlying the
management of lipolysis and thermogenesis by the SNS are continuously explored and expanded
upon as new technological approaches arise. SNS drive also effects hyperplasia in WAT and
BAT, with the former being diminished and the latter being enhanced (Geloen, Collet et al. 1988,
Bronnikov, Bengtsson et al. 1999, Foster and Bartness 2006, Bartness, Liu et al. 2014). Contrary
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to the sustained study of other conditions known to alter AT mass, however, regulation of APC
proliferation by the SNS has not been tested to great extent, especially in WAT.
4.2

Characterization of adipocyte precursor cell content and proliferation
Adipocytes are terminally differentiated while APCs are capable of undergoing mitosis and

ultimately dividing to increase the number of cells. Research on the molecular mechanisms
controlling WAT hyperplasia, therefore, necessitates isolation of adipocyte progenitors and
preadipocytes. When working with primary cells cultured in vitro or conducting experiments in
vivo, APCs must be parsed out from the heterogeneous mixture of cells contained within the SVF
(Lafontan 2012). Past publications purport to have sequestered preadipocytes, in particular, from
the SVF through the use of Percoll gradient separation or immunohistochemical staining with an
antibody against AD3. Neither of these approaches are as comprehensive or reliable as desired,
however. In our lab, we used the Percoll density gradient technique repeatedly with varied
results, finding the final separation between the adipose and stromal vascular layers to be highly
subjective. Difficulties in resolving AD3 staining were also experienced by our lab (Foster and
Bartness 2006).
Phenotyping of APC surface markers and the use of antibodies against these markers to
select for APCs in flow cytometric analyses has been more recently adopted by fellow AT
biologists. Positive staining for the ADSC marker, CD34, along with a lack of CD31 expression
(indicative of vascular endothelial cells) was used by Maumus et al., to characterize progenitor
cells (CD34+: CD31-) from human abdominal subcutaneous AT (Maumus, Sengenes et al.
2008). Luche et al., probed for the presence of the hematopoietic antigen, CD45, in addition to
CD34 and CD31. The authors assign the CD34+: CD31-: CD45- molecular signature to
preadipocytes (Luche, Cousin et al. 2013). Investigation of CD24 expression throughout the
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stages of adipogenesis asserts that CD24 is upregulated in cells undergoing early phases of
differentiation but is downregulated as cells reach maturity in the adipose lineage (Smith,
Fairbridge et al. 2015). The presence of CD24 can thus be used to differentiate between the two
types of APCs, adipocyte progenitors (CD24+) and preadipocytes (CD24-). Although not
attempting to localize APCs specifically, another study used Sca-1 positive staining in flow
cytometry analyses as a marker of cells with adipogenic potential (Staszkiewicz, Gimble et al.
2009).
Rodeheffer et al., bring these observations together with two additional proteins (CD29 and
PdgfRα) to describe a panel of surface markers for flow cytometric analyses that will enrich for
adipocyte progenitors (CD31-: CD45-: CD29+: CD34+: PdgfRα+: CD24+: Sca1+) or
preadipocytes (CD31-: CD45-: CD29+: CD34+: PdgfRα+: CD24-: Sca1+) (Rodeheffer, Birsoy
et al. 2008). In our lab, we have adapted this panel to function optimally in our system and
confidently segregate APCs from the SVF milieu.
In addition to surface staining, we quantify Ki67 protein content in adipocyte progenitors
and preadipocytes. The presence of Ki67 is an indicator of replication, as it is detectable only in
cells in G1, S, G2, and M-phases of the cell cycle. Ki67 has been shown to be necessary for cells
to retain their proliferative capacity and has been used to examine hyperplasia in mouse and
human WAT (Lalor, Mapp et al. 1987, Sasaki, Murakami et al. 1987, Maumus, Sengenes et al.
2008, Rigamonti, Brennand et al. 2011). Analyses of Ki67 expression therefore allows us to
assess effects on proliferation in these cell types. In lieu of Western Blotting for evaluating
intracellular protein levels, we incorporated this intracellular antigen staining protocol into our
preparation of cells for flow cytometry. This strengthens our results because the processing steps
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are minimized (no need to transfer proteins to a membrane, for example) and detection is specific
at the level of individual cells as opposed to an average representation of the cell extract.
Various methods for the characterization of cellular proliferation are available, with Ki67
labeling being just one of several options. Indirect approaches include cell counting, cell viability
assessment with stains such as trypan blue and metabolic activity tests such as the MTT assay.
These indirect techniques have the advantage of being generally less costly and time-consuming
than direct tactics. A disadvantage of relying upon these assays is that they do not necessarily
correspond to the generation of new cells. Cell counts may increase not only when existing cells
divide and multiply, but also when death rates decrease in a population. Metabolic activity might
see an uptick with an enlarged cell population, implying that proliferative activity has been
promoted, but it may also just be indicative of enhanced enzymatic processes in existing, nonproliferating cells (Romar, Kupper et al. 2016).
Direct measurements are preferable and can be obtained by staining cell cycle-associated
proteins, using cytoplasmic proliferation dyes or quantifying nucleoside analog incorporation. In
the past, our lab has tested for hyperplasia using nucleoside analog incorporation with either
tritiated thymidine or BrdU. Both are thymidine analogs and, as such, are reporting on DNA
synthesis that occurs during S-phase. In the present work, we decided against using either
because tritiated thymidine has the significant drawback of being radioactive and BrdU, in our
experience, was not as easily observable as desired in histological staining (Foster and Bartness
2006). We opted instead to label the cell cycle-associated antigen Ki67, which has the benefit of
being detectable in all active stages of the cell cycle, not just the S-phase. Also, nucleoside
analog incorporation is less ideal in cells that undergo multiple rounds of division, as APCs do.
The analog is integrated into newly-synthesized DNA during the first replication, but not
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subsequent mitotic cycles. Still, assessing Ki67 expression requires that cells be fixed then
permeabilized, making this an endpoint assay. In the future, we might want to explore labeling
with the cytoplasmic proliferation dye carboxyfluorescein diacetate succinimidyl ester (CFSE).
CFSE would be conducive to experiments wherein cells are sorted and further manipulated
following flow cytometry analyses (Lyons, Blake et al. 2013).
We chose to culture primary SVF isolated from murine IWAT, rather than a specific WAT
cell type found in a cell line because we see a more direct translation to the in vivo
microenvironment with freshly isolated cells. Clonal cell lines are routinely passaged and more
susceptible to genetic abnormalities (Hausman, Park et al. 2008). An advantage, however, of
working with an adipose precursor cell line is that it consists of only adipogenic cells, or those
that have committed to the adipose lineage (the 3T3-L1 mouse embryonic fibroblasts, for
example). In contrast, the SVF includes many varied cells that support adipocytes and AT
function as a whole. Our decision to use primary SVF cells required us to segregate APCs (our
cells of interest) from the heterogeneous pool of stem cells, blood, endothelial cells,
macrophages, chondrocytes, and so forth. We found multi-color, multi-parameter flow cytometry
analyses to be most precise and effective in separating APCs from other cell types.
4.3

Molecular mechanisms by which the sympathetic nervous system directs adipogenic
cell distribution and hyperplasia in white adipose tissue
A thorough approach utilizing more updated, advanced technology has allowed us to reach

the conclusion that the β1-AR is the specific subtype likely mediating the reduction in WAT
hyperplasia following SNS activation. Downstream of the β1-AR, we anticipate that AMPK
activity is modulated and contributes to the cell cycle regulation. We have initiated investigations
into the role of AMPK but have yet to reach a solid conclusion. Putative mediators further

52

downstream of AMPK include p21 and p27. There is some evidence that these CKIs may be
involved in repressing cell cycle progression, so testing these molecules is of interest as well.
Here we have begun to elucidate the means by which the SNS impacts IWAT APC
proliferation. A future direction that could further empower our results is the study of SNS
regulation of APC proliferation from other WAT depots, such as abdominal subcutaneous WAT.
Heterogeneity between the different WAT depots is increasingly seen in obesity research, so a
more exhaustive exploration of SNS impact on APC proliferation in WAT throughout the body
is warranted (Cleal, Aldea et al. 2017).
4.4

Summary
In summary, this work advances the field of obesity research by furthering our

understanding of WAT biology, specifically in the area of APC proliferation. We began with in
vivo studies, then confirmed and expanded upon our results with in vitro primary cell culture of
the SVF of mouse IWAT. The aim of the experiments presented here is to define the role of the
SNS in regulation of APC proliferation and the underlying AR mediating the SNS’s inhibitory
effect. We show that the SNS has significant capacity to limit APC populations in WAT and that
it does so via the β1-AR. Our results suggest a possible role for AMPK in the downstream
signaling of β1-AR activation, but future studies are warranted to test AMPK and other putative
intracellular effectors in orchestrating SNS suppression of WAT APC proliferation.
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